Underactivity of A/-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission may play a critical role in schizophrenia (SZ) and, in particular, may underlie persistent negative symptoms and cognitive dysfunction. NMDA receptors are regulated in vivo by the amino acids glycine and D-serine, which bind to a modulatory site on the NMDA receptor complex. Studies using full agonists (glycine and D~serine) and a partial agonist (D-cycloserine) of the NMDA receptor added to conventional or atypical antipsychotics have yielded encouraging, but mixed, results due in part to limitations in the pharamacokinetic/pharmacodynamic properties of the compounds themselves. An alternative approach to raising brain glycine levels is administering compounds that block synaptic glycine reuptake in brain via glycine (GLYT1) transporters. GLYT1 transporters are co-localized with NMDA receptors in the brain and function to limit glycine levels in the immediate vicinity of NMDA receptors. Glycine transport inhibitors have proven effective in numerous animal models of SZ. Although high-affinity glycine transport inhibitors have been developed by several pharmaceutical companies, clinical data are, as yet, unavailable. Sarcosine (A/-methylglycine) is a naturally occurring glycine type I (GLYT1) transport inhibitor that has been reported to improve negative symptoms and cognition in both chronic and acutely decompensated patients in studies conducted in Taiwan, but remains unavailable in the US. In this project, we will perform a randomized, placebo-controlled study of sarcosine as add-on treatment to anti-psychotics in first episode schizophrenia patients in Israel. Use of sarcosine has been approved in Israel based upon the successful clinical trials that were conducted in Taiwan. Studies in Israel will be conducted in accordance with FDA GCP and GLP guidelines and will be supported by Data Management/Biostatistic core (Core C). Neurophysiological outcome measures will be incorporated into the study and will be supported by the Patient Assessment/Recruitment core (Core B). The study will also take advantage of the Israeli Draft Board Registry, which provides objective premorbid data on participating subjects. It is hypothesized that impaired premorbid function will predict more severe neurocognitive and neurophysiological deficit, and greater benefit from an NMDA-based approach.

Public Health Relevance

Schizophrenia is a major mental disorder. Neurocognitive dysfunction is a core component of schizophrenia and a major determinant of poor long-term outcome. This project is part of a Center application to determine brain mechanisms underlying neurocognitive dysfunction in schizophrenia with particular emphasis on sensory processing dysfunction. This project will evaluate the effects of the glycine transport inhibitor sarcosine on persistent neurocognitive deficits in schizophrenia. If successful, it will support a new treatment approach for schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH086385-04
Application #
8380058
Study Section
Special Emphasis Panel (ZMH1-ERB-F)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$138,515
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Corcoran, Cheryl M; Stoops, Anastasia; Lee, Migyung et al. (2018) Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia. Schizophr Res 191:101-108
Lee, Migyung; Balla, Andrea; Sershen, Henry et al. (2018) Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia. Neuropsychopharmacology 43:571-582
Brucato, Gary; Appelbaum, Paul S; Masucci, Michael D et al. (2018) Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness. Neuropsychopharmacology :
Kantrowitz, Joshua T; Epstein, Michael L; Lee, Migyung et al. (2018) Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res 191:70-79
Potvin, Olivier; Dieumegarde, Louis; Duchesne, Simon et al. (2017) Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain. Neuroimage 156:315-339
Poe, Sarah-Lucy; Brucato, Gary; Bruno, Nicolina et al. (2017) Sleep disturbances in individuals at clinical high risk for psychosis. Psychiatry Res 249:240-243
Zhao, Jizheng; Li, Mintong; Zhang, Yi et al. (2017) Intrinsic brain subsystem associated with dietary restraint, disinhibition and hunger: an fMRI study. Brain Imaging Behav 11:264-277
Kantrowitz, Joshua T; Nolan, Karen A; Epstein, Michael L et al. (2017) Neurophysiological Effects of Bitopertin in Schizophrenia. J Clin Psychopharmacol 37:447-451
Lee, M; Sehatpour, P; Hoptman, M J et al. (2017) Neural mechanisms of mismatch negativity dysfunction in schizophrenia. Mol Psychiatry 22:1585-1593
Potvin, Olivier; Dieumegarde, Louis; Duchesne, Simon et al. (2017) Freesurfer cortical normative data for adults using Desikan-Killiany-Tourville and ex vivo protocols. Neuroimage 156:43-64

Showing the most recent 10 out of 96 publications